Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737231 | 0.71 | DRD2 (0.36) | DRD2HTR2ADRD3CYP1A2 | |
| Hydrochloric Acid SCHEMBL1698466 | 0.71 | DRD2 (0.70) | DRD2HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL1698592 | 0.71 | DRD2 (0.70) | DRD2HTR2ADRD3 | |
| SCHEMBL1698406 | 0.71 | HTR2C (0.49) | DRD2HTR2ADRD3HTR2C | |
| SCHEMBL16795286 | 0.69 | MEN1 (0.44) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL1698462 | 0.69 | DRD2 (0.48) | DRD2HTR2ADRD3HTR2C | |
| SCHEMBL2366129 | 0.68 | TAAR1 (0.47) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL322004 | 0.68 | HTR2C (0.49) | DRD2HTR2ADRD3HTR2C | |
| Hydrochloric Acid SCHEMBL2366927 | 0.67 | TAAR1 (0.46) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL2366907 | 0.66 | HRH4 (0.48) | MEN1CYP1A2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582705-B1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8586579-B2 | Anellated pyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2582705-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011161009-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-29 | — | — | WO | disclosed |
| US-20110313151-A1 | ANELLATED PYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313151-A1 | ANELLATED PYRIDINE COMPOUNDS | ADORA3, ADORA2A, HTR3A | DRD2 78/4885HTR2A 4/4885DRD3 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.